Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 2/20 | 0.44 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.43 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.43 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.43 |
| ▸ | GSR | P00390 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HRH1 | P35367 | 1/20 | 0.43 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.40 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.39 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | ELANE | P08246 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL27970702 | 0.95 | ATM (0.42) | LTA4HDPP8DPP7DPP9GSR | |
| SCHEMBL7775127 | 0.95 | GSR (0.50) | LTA4HDPP8DPP7DPP9GSR | |
| SCHEMBL7775125 | 0.95 | GSR (0.50) | LTA4HDPP8DPP7DPP9GSR | |
| Phenylacetic Acid SCHEMBL28273739 | 0.90 | AKR1B1 (0.46) | LTA4HDPP8DPP7DPP9MMP2 | |
| SCHEMBL28120129 | 0.90 | ATM (0.44) | LTA4HDPP8DPP7HRH1ATM | |
| SCHEMBL7874885 | 0.88 | LTA4H (0.41) | LTA4HDPP8DPP7DPP9GSR | |
| SCHEMBL28715584 | 0.87 | POLB (0.48) | LTA4HGSRATML3MBTL1SLC1A3 | |
| SCHEMBL8517364 | 0.85 | TDP1 (0.44) | ATML3MBTL1TDP1KMT2A | |
| SCHEMBL24530374 | 0.82 | ATM (0.46) | LTA4HHTR2AATML3MBTL1SLC1A3 | |
| SCHEMBL27639690 | 0.82 | ATM (0.46) | LTA4HHTR2AATML3MBTL1SLC1A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107708684-A | L Ornithine phenylacetate preparation | 欧塞拉治疗有限公司 | 2018-02-16 | — | — | CN | claimed |
| CN-106163528-A | Steroids for the treatment of hepatic encephalopathy | 梅克芳识别有限公司 | 2016-11-23 | — | — | CN | claimed |
| CN-106810464-B | L-ornithine phenyl acetate and preparation method thereof | 欧塞拉治疗有限公司 | 2019-01-22 | — | — | CN | disclosed |
| CN-108366983-A | L Ornithine phenylacetate preparation | 欧塞拉治疗有限公司 | 2018-08-03 | — | — | CN | disclosed |
| CN-107708684-A | L Ornithine phenylacetate preparation | 欧塞拉治疗有限公司 | 2018-02-16 | — | — | CN | disclosed |
| CN-106810464-A | L ornithine phenylacetates and preparation method thereof | 欧塞拉治疗有限公司 | 2017-06-09 | — | — | CN | disclosed |
| CN-104230730-B | L-ORNITHINE PHENYL ACETATE AND METHODS OF MAKING THEREOF | 欧塞拉治疗有限公司 | 2017-05-24 | — | — | CN | disclosed |
| US-9604909-B2 | L-ornithine phenyl acetate and methods of making thereof | OCERA THERAPEUTICS, INC. (US) | 2017-03-28 | — | — | US | disclosed |
| US-20150251990-A1 | L-ORNITHINE PHENYL ACETATE AND METHODS OF MAKING THEREOF | OCERA THERAPEUTICS LLC | 2015-09-10 | — | — | US | disclosed |
| CN-104434894-A | REATMENT OF PORTAL HYPERTENSION USING L-ORNITHINE PHENYLACETATE | OCERA THERAPEUTICS INC | 2015-03-25 | — | — | CN | disclosed |
| CN-104230730-A | L-ORNITHINE PHENYL ACETATE AND METHODS OF MAKING THEREOF | OCERA THERAPEUTICS INC | 2014-12-24 | — | — | CN | disclosed |
| CN-102421432-B | L-ornithine phenylacetate and preparation method thereof | OCERA THERAPEUTICS INC | 2014-09-17 | — | — | CN | disclosed |
| CN-102625699-B | Treatment of portal hypertension and restoration of liver function using L-ornithine phenylacetate | UCL BUSINESS PLC | 2014-08-20 | — | — | CN | disclosed |
| US-20120208885-A1 | L-ORNITHINE PHENYL ACETATE AND METHODS OF MAKING THEREOF | OCERA THERAPEUTICS, INC. (US) | 2012-08-16 | — | — | US | disclosed |
| CN-102625699-A | Treatment of portal hypertension and restoration of liver function using L-ornithine phenylacetate | UCL BUSINESS PLC | 2012-08-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208885-A1 | L-ORNITHINE PHENYL ACETATE AND METHODS OF MAKING THEREOF | OAT, OTC, ODC1 | LTA4H 2711/4885DPP8 1666/4885DPP7 1895/4885 |
| US-20150251990-A1 | L-ORNITHINE PHENYL ACETATE AND METHODS OF MAKING THEREOF | OAT, OTC, ODC1 | LTA4H 2711/4885DPP8 1666/4885DPP7 1895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.